This just published research suggests that you can successfully treat rosacea with Mirvaso and Soolantra at the same time. So if you are suffering from the red face and pustules and papules of rosacea, this paper suggests that using Mirvaso and Soolantra together is a viable option.
Previously Mirvaso and Soolantra have been shown to be more effective than their inactive ingredients, but now this research has shown that used together they maintain their effectiveness and don’t interfere with each other.
Two is better than one?
This paper is part of an ongoing effort by Galderma to show that their rosacea treatments can be used in concert with each other. Earlier this year we learnt that Galderma is also trialing Oracea with Soolantra. In recent years several papers have explored the efficacy of combining Metrogel 1% and Oracea.
The paper was published in a prestigous dermatology journal. One of the authors is listed as a Galderma employee.
Linda Stein Gold MD, Kim Papp MD PhD FRCPC, Charles Lynde MD FRCPC, Edward Lain MD MBA, Melinda Gooderham MSc MD FRCPC, Sandra Johnson MD FAAD, and Nabil Kerrouche MSc.
J Drugs Dermatol. 2017;16(9):909-916.
BACKGROUND: There is currently a lack of data on the simultaneous treatment of different features of rosacea. Individually, ivermectin 1% (IVM) cream and brimonidine 0.33% (BR) gel have demonstrated efficacy on inflammatory lesions and persistent erythema, respectively.
OBJECTIVE: To evaluate the efficacy, safety, patient satisfaction, and optimal timing of administration of IVM associated with BR (IVM+BR) versus their vehicles in rosacea (investigator global assessment [IGA] ≥3).
METHODS: Multicenter, randomized, double-blind study including subjects with rosacea characterized by moderate to severe persistent erythema and inflammatory lesions. The active treatment group included the IVM+BR/12 weeks subgroup (once-daily BR and once-daily IVM for 12 weeks), and the IVM+BR/8 weeks subgroup (once-daily BR vehicle for 4 weeks followed by once-daily BR for the remaining 8 weeks and once-daily IVM for 12 weeks). The vehicle group received once-daily BR vehicle and once-daily IVM vehicle for 12 weeks.
RESULTS: The association showed superior efficacy (IGA success [clear/almost clear]) for erythema and inflammatory lesions in the total active group (combined active subgroups) compared to vehicle (55.8% vs. 36.8%, P=0.007) at week 12. The success rate increased from 32.7% to 61.2% at hour 0 and hour 3, respectively, in the IVM+BR/12 weeks subgroup, and from 28.3% to 50% in the IVM+BR/8 weeks subgroup. Reductions in erythema and inflammatory lesion counts confirmed the additive effect of BR to IVM treatment.
Subjects reported greater improvement in the active subgroups than in the vehicle group, and similar rates for facial appearance satisfaction after the first 4 weeks of treatment in both active subgroups. All groups showed similar tolerability profiles.
CONCLUSION: Concomitant administration of IVM cream with BR gel demonstrated good efficacy and safety, endorsing the comprehensive approach to this complex disease.
Early introduction of BR, along with a complete daily skin care regimen may accelerate treatment success without impairing tolerability.